GlassScriptPhysician profile
Gregory L Swartz
NPI 1740273739
$6,181.44
in general payments reported to CMS, 2019-2025
34 companies · $16.63 in 2025
The $16.63 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $467 · 2020: $73.10 · 2021: $19.33 · 2022: $1,313 · 2023: $2,109 · 2024: $2,184 · 2025: $16.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,309.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,321.90 | 2022-2024 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $785.35 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $693.79 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $529.65 | 2022-2024 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $432.07 | 2019-2025 | |
| Amgen INC. | $363.44 | 2022-2024 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $240.66 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.44 | 2022-2024 | Jardiance |
| Exact Sciences Corporation | $148.90 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $135.36 | 2022-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $124.72 | 2022-2024 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $115.41 | 2022-2023 | |
| Dexcom, INC. | $105.49 | 2022-2024 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $105.34 | 2023-2024 | Auvelity |
| Astellas Pharma US INC | $100.06 | 2023-2024 | Veozah, Myrbetriq |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $78.31 | 2022-2023 | Belsomra, Steglatro, Steglujan |
| Paratek Pharmaceuticals, INC. | $77.18 | 2022-2023 | Nuzyra |
| Lundbeck LLC | $71.94 | 2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $65.12 | 2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $59.93 | 2022-2024 | Eliquis |
| Biohaven Pharmaceutical Holding Company LTD. | $59.17 | 2022 | |
| Idorsia Pharmaceuticals US INC | $52.91 | 2022-2023 | Quviviq |
| Abbott Laboratories | $52.11 | 2023-2024 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $45.28 | 2024 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.11 | 2024 | Caplyta |
| Amarin Pharma, INC. | $32.59 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $29.94 | 2022 | |
| Nestle Healthcare Nutrition INC. | $26.24 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $25.42 | 2019 | |
| Ironshore Pharmaceuticals INC. | $24.50 | 2024 | |
| Shield Therapeutics INC | $15.24 | 2024 | |
| Kyowa Kirin, INC. | $14.24 | 2023 | Crysvita |
| Tris Pharma INC | $12.70 | 2020 | |
| Shire North American Group INC | $11.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Swartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.